Wednesday, 27 October 2021


RoosterBio inks agreement with Sartorius Korea Biotech

07 December 2020 | News

The partnership with Sartorius launches RoosterBio’s first international platform with off-the-shelf working cell banks and hMSC bioprocess media products in Asia

Photo Credit: Freepik

Photo Credit: Freepik

RoosterBio, Inc, a leading supplier of innovative cellular therapy bioprocess tools and scalable manufacturing solutions for regenerative medicine, has entered into an exclusive agency agreement with Sartorius Korea Biotech, a subsidiary of the Sartorius Group, a leading international partner of the biopharmaceutical and life science research sectors.

This strategic partnership combines Sartorius’ proven expertise in providing high-caliber bioprocess testing, technical and customer services to the local South Korean market, as well as its global reach, and RoosterBio’s advanced platform of RUO and cGMP-grade human mesenchymal stem/stromal cell (hMSC) working cell banks, optimized paired media, and hMSC bioprocess systems. This winning combination sets the stage for accelerating the development of new, effective medical treatments and expands RoosterBio’s footprint into Asia, especially in South Korea.

“South Korea is a preeminent innovator in hMSCs, and the South Korean biotech ecosystem has been flourishing according to every measure of growth. One of the first MSC therapies was developed in Korea, clearing an entirely new path to treat previously incurable diseases,” said RoosterBio CEO Margot Connor. “We are delighted to be working with Sartorius Korea Biotech in our global effort to industrialize the supply chain for next-gen treatments, and we are committed to accelerating the commercialization of cell- and gene-based therapies.”

Under the terms of the agreement, Sartorius Korea Biotech will engage with its customers as an exclusive agent for RoosterBio to facilitate sales operations and increase the market potential for RoosterBio products on an exclusive basis in South Korea.

“RoosterBio’s commercialized product systems standardize hMSC manufacturing to remove years of time and millions of dollars from the timeline of traditional mesenchymal cell therapeutic product development and clinical translation efforts,” said Duck Sang Kim, Managing Director of Sartorius Korea Biotech.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account